Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of patients with relapsed or refractory or R/R, follicular ...

William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...

Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (Genmab's share of gross profits). Genmab expects its 2025 revenue to be in the ...

Acquisition: $1.8 billion acquisition of ProfoundBio. Share Buyback: $500 million in 2024. EPKINLY Sales: $281 million in 2024. Tivdak Sales: $131 million in 2024. Recurring Revenue Growth ...

2024 was a year of strong execution and disciplined investments, driving 31% total revenue growth, fueled by the success of our eight commercialized medicines, including EPKINLY and TIVDAK.

“With EPKINLY® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

With a portfolio of marketed products, including EPKINLY, TEPKINLY, and Tivdak, and a robust pipeline featuring Epcoritamab and tisotumab vedotin, it’s advancing groundbreaking treatments in ...

"With EPKINLY ® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the potential of ...

Most products closed the year strong with Darzalex royalties leading the way. Epkinly net sales were $78 million, and this was slightly lower than expected due to one-time adjustments in France ...

On February 20, the company announced that Japan has approved EPKINLY (epcoritamab) to treat follicular lymphoma (FL) in patients who have already tried at least two other treatments. This makes ...